MedTrace Logo

CuraLin Herbal Supplement for Type 2 Diabetes

NCT05267925 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-04-05

No results posted yet for this study

Summary

The purpose of this study is to provide preliminary data necessary for a larger, controlled trial of CuraLin as a treatment option for T2DM. This study will also fill the gap in literature surrounding herbal medicine in the treatment of T2DM. The use of herbal preparations for diabetes has increased globally, and given the costs, adverse effects, lack of clinical outcome improvement, and minimal A1c reductions associated with medications, safer, more affordable alternatives need to be explored. CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs taken three times daily, after meals for the management of diabetes. It is hypothesized that CuraLin will be safely tolerated among adults with Type 2 Diabetes Mellitus, and will improve glucose control and cardiometabolic risk factors over this 12 week study.

Conditions

Interventions

DIETARY_SUPPLEMENT

CuraLin

CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs. The CuraLin formulation contains the following ingredients (per 2 capsules): * Mormordica charantia (fruit) - 300mg * Gymnema sylvestre (leaf) - 80mg * Trigonella foenum-Graecum (seed) - 100mg * Curcuma longa (rhizome) - 100mg * Phyllanthus embilica officinalis (fruit) - 100mg * Swertia chiraytia (leaf) - 80mg * Syzgium Cumini (seed) - 100mg * Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg * Cinnamoum verum/zeylanicum - 40 mg * Hydroxypropyl methylcellulose * Rice Flour

Sponsors & Collaborators

  • National University of Natural Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-08
Primary Completion
2022-04-14
Completion
2022-04-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05267925 on ClinicalTrials.gov